What are the possible causes of elevated liver function tests in a hospitalized patient?

Causes of Elevated LFTs in Hospitalized Patients

In hospitalized patients with elevated liver function tests, you must first determine the pattern of injury (hepatocellular vs. cholestatic) and then systematically rule out drug-induced liver injury, ischemic hepatitis, sepsis-related liver dysfunction, and acute viral hepatitis—as these are the most common and immediately life-threatening causes in the inpatient setting. 1, 2

Pattern Recognition: The Critical First Step

The pattern of LFT elevation directs your entire diagnostic approach 1:

Hepatocellular Pattern (ALT/AST >> ALP)

• ALT/AST elevated disproportionately compared to alkaline phosphatase
• ALT is more specific for liver injury than AST (which can come from heart, muscle, kidney, brain, RBCs) 1
• Severity classification matters:
  • Mild: <5× upper limit of normal (ULN)
  • Moderate: 5-10× ULN
  • Severe: >10× ULN 1

Cholestatic Pattern (ALP >> ALT/AST)

• ALP elevated disproportionately with or without bilirubin elevation
• Suggests biliary obstruction or impaired bilirubin uptake 1
• If ALP isolated, confirm hepatic origin with GGT 3

Most Common Causes in Hospitalized Patients

1. Drug-Induced Liver Injury (DILI)

This is your first consideration in any hospitalized patient 4, 2:

• Review all medications and supplements including:

  • Antibiotics (especially sulbactam/cefoperazone, meropenem, tazobactam/piperacillin) 5
  • Common culprits: lansoprazole, furosemide, ambroxol, NSAIDs 5
  • Herbal/traditional medications 6
  • Total parenteral nutrition (TPN) 6

• Stop unnecessary hepatotoxic drugs immediately 3, 4

2. Ischemic/Hypoxic Hepatitis ("Shock Liver")

Critical to identify in the ICU setting 2:

• Results from hypoperfusion: sepsis, cardiogenic shock, right heart failure
• Typically shows dramatic aminotransferase elevations (often >1000 IU/L)
• Check for hemodynamic instability, hypotension episodes

3. Sepsis-Related Liver Dysfunction

• Common in critically ill patients 2
• Part of multi-organ dysfunction
• May show mixed hepatocellular-cholestatic pattern

4. Acute Viral Hepatitis

Must be excluded urgently 1, 4:

First-line serologies:

• Hepatitis A: Anti-HAV IgM
• Hepatitis B: HBsAg, Anti-HBc (IgG and IgM), HBV DNA
• Hepatitis C: Anti-HCV, HCV RNA
• Hepatitis E: Anti-HEV (IgG, IgM), HEV RNA 4

Second-line (if indicated):

• EBV, CMV, HSV serologies and PCR 4

5. Acute Budd-Chiari Syndrome

• Hepatic vein thrombosis
• Consider in patients with hypercoagulable states 1

6. Exacerbation of Pre-existing Liver Disease

• Acute-on-chronic liver failure
• Alcohol-related liver disease decompensation 2
• HBV reactivation (especially with immunosuppression) 7

Immediate Workup Algorithm

Step 1: Determine Timing

Was the LFT elevation present before admission or new? 8

• If pre-existing: focus on acute decompensation triggers
• If new: focus on hospital-acquired causes

Step 2: Pattern-Specific Initial Testing

For Hepatocellular Pattern 1, 4:

• Viral hepatitis panel (HAV, HBV, HCV, HEV)
• Autoimmune markers: ANA, ASMA, quantitative immunoglobulins
• Iron studies (ferritin, TIBC, transferrin saturation)
• Ceruloplasmin (if age <40 and no clear cause)
• Creatine kinase (to exclude muscle source of AST)
• Medication review and toxicology screen

For Cholestatic Pattern 1:

• Right upper quadrant ultrasound (first-line imaging)
• GGT to confirm hepatic origin of ALP
• Consider CT/MRCP if obstruction suspected
• Evaluate for secondary sclerosing cholangitis in critically ill (SC-CIP) 2

Step 3: Assess Severity and Synthetic Function

Check for acute liver failure indicators 8:

• INR/PT (synthetic function)
• Albumin (synthetic function)
• Total and direct bilirubin
• Platelet count
• Mental status (hepatic encephalopathy)

Step 4: Imaging

Ultrasound abdomen is first-line for most cases 1:

• Evaluates for steatosis, biliary obstruction, masses, vascular patency
• 84.8% sensitivity, 93.6% specificity for moderate-severe steatosis 1

Special Hospitalized Patient Considerations

COVID-19 Patients

• Abnormal LFTs in 70% of hospitalized COVID-19 patients 9
• AST and total bilirubin elevations most strongly predict mortality 9
• Monitor closely if on potentially hepatotoxic COVID therapies 7

Patients on Immunosuppression

• HBV reactivation risk with corticosteroids or biologics 7
• Screen HBsAg before starting immunosuppression ≥7 days 7
• Initiate antiviral prophylaxis if HBsAg positive 7

ICU Patients

Higher frequency of monitoring needed 7, 2:

• Twice weekly LFTs if on hepatotoxic medications
• More frequent if abnormal and worsening
• Consider SC-CIP if prolonged ICU stay with cholestasis 2

Critical Pitfalls to Avoid

1. Don't assume fatty liver without excluding serious causes 1, 10—NAFLD is common but diagnosis of exclusion

2. AST predominance (AST:ALT >2) suggests:

   • Alcohol-related liver disease 1
   • Cirrhosis
   • Non-hepatic sources (hemolysis, myopathy, thyroid disease, exercise) 1

3. Normal LFTs don't exclude cirrhosis 11—consider Fibroscan in high-risk patients

4. Infliximab is contraindicated in hepatic injury 3—critical for immune-related hepatitis management

5. Don't delay stopping hepatotoxic drugs while awaiting workup 3, 4

6. Isolated ALP elevation: confirm hepatic origin with GGT before extensive hepatic workup 3—may be bone, placental, or intestinal origin

When to Escalate Care

Immediate hepatology consultation if 3, 8:

• ALT/AST >5× ULN with symptoms
• Any elevation with elevated bilirubin (>1.5× ULN) or INR
• Evidence of acute liver failure (encephalopathy, coagulopathy)
• Steroid-refractory immune-mediated hepatitis
• Unclear diagnosis after initial workup

Consider liver biopsy when 3, 4, 12:

• Serologic testing and imaging non-diagnostic
• Multiple possible diagnoses
• Steroid-refractory cases
• Need to stage disease severity